64 related articles for article (PubMed ID: 8825620)
1. Inhibition of human immunodeficiency virus infection by heparin derivatives.
Clayette P; Moczar E; Mabondzo A; Martin M; Toutain B; Marcé D; Dormont D
AIDS Res Hum Retroviruses; 1996 Jan; 12(1):63-9. PubMed ID: 8825620
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the human leukocyte endopeptidases elastase and cathepsin G and of porcine pancreatic elastase by N-oleoyl derivatives of heparin.
Baici A; Diczházi C; Neszmélyi A; Móczár E; Hornebeck W
Biochem Pharmacol; 1993 Nov; 46(9):1545-9. PubMed ID: 8240409
[TBL] [Abstract][Full Text] [Related]
3. Boromycin, an anti-HIV antibiotic.
Kohno J; Kawahata T; Otake T; Morimoto M; Mori H; Ueba N; Nishio M; Kinumaki A; Komatsubara S; Kawashima K
Biosci Biotechnol Biochem; 1996 Jun; 60(6):1036-7. PubMed ID: 8695905
[TBL] [Abstract][Full Text] [Related]
4. Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus.
Ichimura H; Levy JA
Virology; 1995 Aug; 211(2):554-60. PubMed ID: 7544050
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad-spectrum antiviral agents.
Yamamoto N; Schols D; De Clercq E; Debyser Z; Pauwels R; Balzarini J; Nakashima H; Baba M; Hosoya M; Snoeck R
Mol Pharmacol; 1992 Dec; 42(6):1109-17. PubMed ID: 1282664
[TBL] [Abstract][Full Text] [Related]
6. Preparation and anti-HIV activity of O-acylated heparin and dermatan sulfate derivatives with low anticoagulant effect.
Bârzu T; Level M; Petitou M; Lormeau JC; Choay J; Schols D; Baba M; Pauwels R; Witvrouw M; De Clercq E
J Med Chem; 1993 Nov; 36(23):3546-55. PubMed ID: 8246223
[TBL] [Abstract][Full Text] [Related]
7. Effect of Evans blue and trypan blue on syncytia formation and infectivity of human immunodeficiency virus type I and type II in vitro.
Pal R; Mumbauer S; Hoke G; Larocca R; Myers C; Sarngadharan MG; Stein CA
AIDS Res Hum Retroviruses; 1991 Jun; 7(6):537-43. PubMed ID: 1718343
[TBL] [Abstract][Full Text] [Related]
8. In vitro assessment of compounds for anti-HIV activity.
Patience C; Moore J; Boyd M
Mol Biotechnol; 1994 Feb; 1(1):49-58. PubMed ID: 7532100
[TBL] [Abstract][Full Text] [Related]
9. Investigations into the mechanism by which sulfated polysaccharides inhibit HIV infection in vitro.
McClure MO; Moore JP; Blanc DF; Scotting P; Cook GM; Keynes RJ; Weber JN; Davies D; Weiss RA
AIDS Res Hum Retroviruses; 1992 Jan; 8(1):19-26. PubMed ID: 1346567
[TBL] [Abstract][Full Text] [Related]
10. Potent inhibition of human immunodeficiency virus by MDL 101028, a novel sulphonic acid polymer.
Taylor DL; Brennan TM; Bridges CG; Mullins MJ; Tyms AS; Jackson R; Cardin AD
Antiviral Res; 1995 Oct; 28(2):159-73. PubMed ID: 8585769
[TBL] [Abstract][Full Text] [Related]
11. Structure-function relations of heparin-mimetic sulfated xylan oligosaccharides: inhibition of human immunodeficiency virus-1 infectivity in vitro.
Stone AL; Melton DJ; Lewis MS
Glycoconj J; 1998 Jul; 15(7):697-712. PubMed ID: 9881776
[TBL] [Abstract][Full Text] [Related]
12. CD8+ cells from asymptomatic human immunodeficiency virus-infected individuals suppress superinfection of their peripheral blood mononuclear cells.
Barker E; Bossart KN; Locher CP; Patterson BK; Levy JA
J Gen Virol; 1996 Dec; 77 ( Pt 12)():2953-62. PubMed ID: 9000085
[TBL] [Abstract][Full Text] [Related]
13. Low anticoagulant heparin retains anti-HIV type 1 activity in vitro.
Coombe DR; Harrop HA; Watton J; Mulloy B; Barrowcliffe TW; Rider CC
AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1393-6. PubMed ID: 8573397
[TBL] [Abstract][Full Text] [Related]
14. Genomic sites of human immunodeficiency virus type 2 (HIV-2) integration: similarities to HIV-1 in vitro and possible differences in vivo.
MacNeil A; Sankalé JL; Meloni ST; Sarr AD; Mboup S; Kanki P
J Virol; 2006 Aug; 80(15):7316-21. PubMed ID: 16840312
[TBL] [Abstract][Full Text] [Related]
15. Antiviral effects of milk proteins: acylation results in polyanionic compounds with potent activity against human immunodeficiency virus types 1 and 2 in vitro.
Swart PJ; Kuipers ME; Smit C; Pauwels R; deBéthune MP; de Clercq E; Meijer DK; Huisman JG
AIDS Res Hum Retroviruses; 1996 Jun; 12(9):769-75. PubMed ID: 8738428
[TBL] [Abstract][Full Text] [Related]
16. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
McMahon JB; Buckheit RW; Gulakowski RJ; Currens MJ; Vistica DT; Shoemaker RH; Stinson SF; Russell JD; Bader JP; Narayanan VL; Schultz RJ; Brouwer WG; Felauer EE; Boyd MR
J Pharmacol Exp Ther; 1996 Jan; 276(1):298-305. PubMed ID: 8558446
[TBL] [Abstract][Full Text] [Related]
17. Both virus and host components are important for the manifestation of a Nef- phenotype in HIV-1 and HIV-2.
Ryan-Graham MA; Peden KW
Virology; 1995 Oct; 213(1):158-68. PubMed ID: 7483259
[TBL] [Abstract][Full Text] [Related]
18. The potential for heparin and its derivatives in the therapy and prevention of HIV-1 infection.
Rider CC
Glycoconj J; 1997 Aug; 14(5):639-42. PubMed ID: 9298697
[TBL] [Abstract][Full Text] [Related]
19. Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity.
Jansen RW; Schols D; Pauwels R; De Clercq E; Meijer DK
Mol Pharmacol; 1993 Nov; 44(5):1003-7. PubMed ID: 7902528
[TBL] [Abstract][Full Text] [Related]
20. Novel sulfated polysaccharides: dissociation of anti-human immunodeficiency virus activity from antithrombin activity.
Baba M; De Clercq E; Schols D; Pauwels R; Snoeck R; Van Boeckel C; Van Dedem G; Kraaijeveld N; Hobbelen P; Ottenheijm H
J Infect Dis; 1990 Feb; 161(2):208-13. PubMed ID: 2405068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
